In the case of MDM2 inhibitors, the dose-limiting toxicities are hematological (neutropenia and thrombocytopenia [17,35], whereas for trametinib, the dose-limiting toxic effects include rash, diarrhea, and central serous retinopathy [36]. Here, MDM2 is linked to Decreased total neutrophil count.